Identifying patients for treatment with YESCARTA® | GileadPro

Treatment guidelines for CAR T-cell therapy in R/R LBCL

BSH now recommend CAR T-cell therapy, including YESCARTA®, as a standard of care for eligible patients with R/R LBCL that relapse within 12 months of 1L CIT, and as 3L therapy in patients who relapse beyond 12 months of 1L CIT who did not receive CAR T as 2L¹

Figure adapted from Chaganti S, et al. Br J Haematol 2025.¹
* Glofit-GemOx is recommended, where available, in preference to R-GemOx.

BSH guidelines recommend assessing eligibility and fitness for CAR T-cell therapy and HDT-auto in all patients with R/R LBCL as soon as possible¹

• For those not suitable for 2L CAR T-cell therapy (or HDT-auto), treatment should be based on patient fitness, prior 1L therapy and suitability for CAR T-cell therapy (or anti-CD3xCD20 bispecific therapy) in the 3L setting

Following disease assessment at relapse, BSH recommend restaging with PET-CT¹

• Response should be assessed prior to reinduction with a PET-CT scan after two to three cycles (with HDT-auto offered to patients achieving a CMR)

Patient eligibility criteria for YESCARTA® in the real world vs clinical studies

EBMT and EHA recommendations for minimal organ function for CAR T-cell therapy eligibility may be more permissive than criteria used in pivotal clinical studies^2,3

EBMT also recommend that medical history, performance status and CAR T product should be considered with respect to tolerability³